An acne deal this year is "entirely possible" according to CEO

Botanix (ASX:BOT) is moving down a route that other ASX pot stocks are only just getting started on — pure pharmaceutical drug maker.

Data from the Phase 1b study on the psoriasis treatment is due in April.

Then comes the acne phase 2 data by September, followed by the dermatitis phase 2 towards the end of 2019.

And it plans to have a study designed for the new anti-microbial skin infection indication “within the next quarter or two”.

As dermatology treatments are typically licensed or partnered up after phase 2 results are in, it’s “entirely possible” Botanix has a deal on the table for the acne drug this year.

https://unauthorised investment advice/health/the-pot-seat-botanixs-matt-callahan-says-synthetics-are-the-future-of-cannabis-drugs/